Jubilant Pharmova Limited - Laporan Laba Rugi (TTM)

Jubilant Pharmova Limited
IN ˙ BSE
₹ 897.30 ↑0.95 (0.11%)
2025-04-30
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Jubilant Pharmova Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 89,744 92,659 60,985 65,771 66,432 61,824 61,302 59,472 58,893 61,313 62,817 64,169 64,977 66,223 67,029 68,477 69,197 70,643 72,345 74,035
Change (%) 3.25 -34.18 7.85 1.00 -6.94 -0.84 -2.98 -0.97 4.11 2.45 2.15 1.26 1.92 1.22 2.16 1.05 2.09 2.41 2.34
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 30,549 32,300 15,360 17,709 16,473 14,623 14,880 15,144 15,583 17,629 20,816 20,110 20,852 21,430 23,513 21,823 23,904 24,289 25,357 23,735
Change (%) 5.73 -52.45 15.29 -6.98 -11.23 1.76 1.77 2.90 13.13 18.08 -3.39 3.69 2.77 9.72 -7.19 9.54 1.61 4.40 -6.40
% of Revenue 34.04 34.86 25.19 26.92 24.80 23.65 24.27 25.46 26.46 28.75 33.14 31.34 32.09 32.36 35.08 31.87 34.54 34.38 35.05 32.06
Gross Operating Profit 59,196 60,359 45,625 48,062 49,959 47,201 46,422 44,328 43,310 43,683 42,001 44,059 44,125 44,793 43,516 46,654 45,293 46,354 46,988 50,300
Change (%) 1.96 -24.41 5.34 3.95 -5.52 -1.65 -4.51 -2.30 0.86 -3.85 4.90 0.15 1.51 -2.85 7.21 -2.92 2.34 1.37 7.05
% of Revenue 65.96 65.14 74.81 73.08 75.20 76.35 75.73 74.54 73.54 71.25 66.86 68.66 67.91 67.64 64.92 68.13 65.46 65.62 64.95 67.94
SG&A 22,527 22,683 19,440 19,448 19,875 20,300 20,739 20,734 21,292 21,726 22,151 21,845 22,308 22,444 22,873 22,212 23,250 23,036 23,431 23,061
Change (%) 0.69 -14.30 0.04 2.20 2.14 2.16 -0.02 2.69 2.04 1.96 -1.38 2.12 0.61 1.91 -2.89 4.67 -0.92 1.71 -1.58
% of Revenue 25.10 24.48 31.88 29.57 29.92 32.83 33.83 34.86 36.15 35.43 35.26 34.04 34.33 33.89 34.12 32.44 33.60 32.61 32.39 31.15
R&D
Change (%)
% of Revenue
OpEx 75,794 78,569 49,543 53,400 53,344 51,695 52,903 53,620 53,537 56,450 59,068 62,126 61,204 61,732 61,798 62,479 62,629 63,348 64,311 65,677
Change (%) 3.66 -36.94 7.79 -0.11 -3.09 2.34 1.35 -0.15 5.44 4.64 5.18 -1.49 0.86 0.11 1.10 0.24 1.15 1.52 2.12
% of Revenue 84.46 84.79 81.24 81.19 80.30 83.62 86.30 90.16 90.91 92.07 94.03 96.82 94.19 93.22 92.20 91.24 90.51 89.67 88.89 88.71
Operating Income 13,950 14,090 11,443 12,371 13,089 10,129 8,398 5,853 5,355 4,862 3,749 2,043 3,774 4,492 5,231 5,998 6,568 7,295 8,034 8,358
Change (%) 1.00 -18.79 8.11 5.80 -22.61 -17.09 -30.31 -8.49 -9.21 -22.90 -45.50 84.70 19.03 16.46 14.66 9.50 11.07 10.13 4.03
% of Revenue 15.54 15.21 18.76 18.81 19.70 16.38 13.70 9.84 9.09 7.93 5.97 3.18 5.81 6.78 7.80 8.76 9.49 10.33 11.11 11.29
Interest Expense -2,684 -2,607 -1,734 -1,708 -1,483 -1,386 -1,382 -1,508 -1,508 -1,649 -1,686 -2,102 -2,147 -2,353 -2,564 -2,814 -2,604 -2,447 -2,209 -2,183
Change (%) -2.86 -33.51 -1.48 -13.15 -6.57 -0.24 9.08 0.02 9.33 2.24 24.67 2.14 9.60 8.97 9.75 -7.46 -6.03 -9.73 -1.18
% of Revenue -2.99 -2.81 -2.84 -2.60 -2.23 -2.24 -2.26 -2.54 -2.56 -2.69 -2.68 -3.28 -3.30 -3.55 -3.83 -4.11 -3.76 -3.46 -3.05 -2.95
Net Income 7,759 8,825 8,359 9,084 8,272 5,683 4,139 3,004 1,631 964 -610 -1,017 -446 378 771 5,528 5,931 6,272 8,394 4,602
Change (%) 13.73 -5.28 8.68 -8.94 -31.30 -27.16 -27.42 -45.72 -40.88 -163.27 66.69 -56.16 -184.84 103.86 616.99 7.29 5.75 33.83 -45.18
% of Revenue 8.65 9.52 13.71 13.81 12.45 9.19 6.75 5.05 2.77 1.57 -0.97 -1.58 -0.69 0.57 1.15 8.07 8.57 8.88 11.60 6.22

Source: Capital IQ

Other Listings
IN:JUBLPHARMA ₹ 1,069.70
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista